Morningstar remains optimistic on Ebos Group, says shares are 'undervalued'
BUZZ-Morningstar remains optimistic on Ebos Group, says shares are 'undervalued' ** Analysts at Morningstar are hopeful of healthcare distribution firm EBOS Group EBO.AX, EBO.NZ improving its profitability in the long term
** Says decreasing exposure to lower-margin pharmacy distribution will help co
** Investment research firm forecasts a five-year group revenue compound annual growth rate of 5%
** Adds medical technology, logistics, and animal care segments will see the strongest growth
** "Ebos faces some short-term headwinds, such as tightening hospital budgets, and higher fuel prices driving up costs of transportation and packaging, we expect these to be mostly temporary," Morningstar says
** Says shares are undervalued, keeps fair value estimate of A$29 per share and NZ$35 apiece
** YTD, both NZ & ASX-listed shares are down around 30%
(Reporting by Rajasik Mukherjee in Bengaluru)
Recent news on EBOS
See all newsASX-listed EBOS Group set for best day in 9 years on strong annual results
Brief: EBOS Group Announces Final Dividend Of NZ 61.5 Cents Per Share
Brief: EBOS Group Says Capital Expenditure Is Expected To Normalise To Approximately A$100 Million In FY27
Ebos Group rises as Morningstar remains optimistic, says shares are 'undervalued'
Morningstar remains optimistic on Ebos Group, says shares are 'undervalued'